Fungal Infections and Studies
Peer reviewed
Scollr summary
What this paper is about
Olorofim showed effectiveness in patients with DCM with limited or no therapeutic options with limited or no therapeutic options in a single-group, open-label, phase 2b study.
Full abstract
Read the full abstract
BACKGROUND: Olorofim, a novel dihydroorotate dehydrogenase inhibitor, may be efficacious in patients with disseminated coccidioidomycosis (DCM) who lack alternative treatment options. OBJECTIVE: To evaluate olorofim effectiveness and adverse events in patients with DCM. DESIGN: Single-group, open-label, phase 2b study. (ClinicalTrials.gov: NCT03583164). SETTING: Ten U.S. sites. PARTICIPANTS: Forty-one patients with DCM and limited or no treatment options. Patients received olorofim alone or in combination with ongoing standard of care during an 84-day main treatment phase. Extended treatment was offered to patients. MEASUREMENTS: Mycoses Study Group-European Organization for Research and Treatment of Cancer (MSG-EORTC) criteria for global response based on subcategories of clinical, radiologic, and mycologic response were adjudicated by an independent data review committee (DRC) at days 42 and 84 (main treatment phase). Because the slow pace of serologic improvement in DCM limits global response to stable at best, this article focuses on patient clinical responses. Treatment-emergent adverse events (TEAEs) were compiled for both treatment phases. RESULTS: Forty-one patients with DCM were enrolled from May 2019 to August 2022. Thirty-nine (95.1%) did not have immunosuppression. Central nervous system disease was present in 30 (73.2%) patients, and 13 (43.3%) had a ventriculoperitoneal shunt with or without an Ommaya reservoir. Clinical success as adjudicated by the DRC occurred in 31 of 41 patients (75.6% [95% CI, 59.7% to 87.6%]) at day 42 and 30 of 41 patients (73.2% [CI, 57.1% to 85.8%]) at day 84. The main TEAE was hepatic biochemistry elevation in 9 of 41 patients (21.9%), which was managed by liver enzyme monitoring and dose reduction or pause in 8 patients (19.5%) and drug discontinuation in 1 patient (2.4%). LIMITATION: This was a single-group, open-label trial, but a randomized controlled trial would be preferable. CONCLUSION: Olorofim showed effectiveness in patients with DCM with limited or no therapeutic options. PRIMARY FUNDING SOURCE: F2G, Ltd.
Direct answer
What can I do from this paper page?
Use this page to scan "Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Fungal Infections and Studies research, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{Donovan2026Olorofim,
title = {Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis},
author = {Fariba Donovan and Royce H. Johnson and Thomas F. Patterson and Martin Hoenigl and Andrej Spec and Monica K Sikka and Steven M. Holland and Shmuel Shoham and Joanna Schaenman and Sanjay R. Mehta and Rasha Kuran and John N. Galgiani and Mark Bresnik and John Rex and George R. Thompson},
journal = {Annals of Internal Medicine},
year = {2026},
doi = {10.7326/annals-26-00103},
url = {https://doi.org/10.7326/annals-26-00103}
}FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new Fungal Infections and Studies research papers?
Follow Fungal Infections and Studies research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app